Retrospective analysis of the MEK2 mutations in serial plasma samples collected through the patient’s treatment course revealed emergence of these mutant alelles in concert with increases in fractional abundance of mutant BRAF and TP53 alleles (Figure 5E). Thus, these data likely reflect the emergence of heterogeneous polyclonal resistance mechanisms that evolved under the selective pressure of trametinib therapy.